MedTrace Logo

New Methods for Evaluating Preventive Migraine Treatment

NCT07071506 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-05-19

No results posted yet for this study

Summary

The study aims to test interactions between drug and placebo-responses in acute migraine treatment and to assess variation in adverse events according to treatment information provided. Using a clinical within-subjects, balanced placebo design, patients with chronic migraine will receive four treatment conditions in a randomized order.

Conditions

  • Migraine
  • Migraine With or Without Aura
  • Headache Disorders
  • Chronic Migraine, Headache

Interventions

DRUG

Active drug for chronic migraine treatment.

Standard dose of Fremanezumab, 225 mg (Ajovy) injected subcutaneously

DRUG

Placebo Subcutaneous injection

Inactive placebo (saline) injected subcutaneously in the same volume as the active drug

Sponsors & Collaborators

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Lene Vase, MSc, PhD, DMSc · Dept. of Psychology and Behavioural Sciences, Aarhus University, Aarhus, Denmark

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-19
Primary Completion
2028-09-30
Completion
2028-09-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07071506 on ClinicalTrials.gov